BBlogFlow

Climates of Health: The Weather Inside Us - University of Alberta

·Aug 14, 2026
Source: University of Alberta
Read the original article

This story deserves to be shared

Send it to someone who'd care, or post it on your networks.

Facebook Twitter Email

This article is an excerpt. To read the full content, visit the original source. University of Alberta

Reactions

0 comments

No comments yet. Be the first to share your thoughts!

Facebook Twitter

Related articles

Exhibit Review: ‘Climates of Health: The Weather Inside Us’ - The Gateway Online

Monet Davies from the forests to the glaciers, into my lungs by Johnathan S. Green If there is one thing that Climates of Health: The Weather Inside Us invokes, it is our oneness with the environment. With contributing artists from Canada, Japan, and the United States, this exhibit at the FAB Gallery makes us reflect on how all of us experience this “interprobleminary” life in different ways, yet the worsening climate crisis impacts every one of us. We are called to confront the ways in which we are interlinked with climate change, from the consumerism that fuels it to the vulnerable communities and immunocompromised individuals who suffer most from it.  In artist Yoomi Nam’s work, “Unfolding” and “Keeping,” we are disoriented by the familiar. I was confused by the prints of “Unfolding,” which stretched up the wall with overlapping shadows of shapes that reminded me of something I could not quite place my finger on. The same went for “Keeping,” the smooth, sage green porcelain pieces positioned firmly in the centre of the room.

The Gateway Online·

Bioengineer.org | Viral blips during HIV therapy are common and rarely signal treatment failure, Swedish study finds - European AIDS Treatment Group

Bioengineer.org news storyFor people living with HIV, modern antiretroviral therapy can suppress the virus to levels below what standard laboratory tests can detect. Yet some patients on long-term treatment experience a curious phenomenon: a single test result showing a small, transient amount of virus in the blood, followed by an immediate return to undetectable levels. These events, known as viral blips, have puzzled clinicians and researchers for years, raising questions about whether they represent harmless statistical noise, brief bursts of viral production from hidden reservoirs, or early warnings of impending treatment failure. A new nationwide Swedish study, published in BMC Infectious Diseases, offers one of the most comprehensive answers to date. Drawing on the Swedish national InfCareHIV cohort, researchers analyzed data from 4,210 treatment-naïve adults who began antiretroviral therapy from 1 January 2007 onward, with follow-up data extracted through 30 September 2020. The median observation time was 5.5 years, with some individuals followed for as long as 13.7 years.

European AIDS Treatment Group·

European Medical Journal | HIV linked to early signs of heart dysfunction - European AIDS Treatment Group

European Medical Journal news storyPeople living with HIV may experience subtle changes in heart muscle function even when conventional measures of cardiac performance remain normal, according to findings from a systematic review and meta-analysis. Researchers identified significantly impaired global longitudinal strain (GLS) among people with HIV compared with HIV-uninfected individuals, despite preserved left ventricular ejection fraction (LVEF) in both groups. The findings suggest that speckle-tracking echocardiography (STE) could provide additional information about early myocardial dysfunction in this population. Read the full news story here.

European AIDS Treatment Group·

Patient-centered financial navigation assistance helps reduce financial toxicity among cancer patients - Medical Xpress

Among cancer patients, the high financial cost of cancer care is a prevalent problem. This financial burden is also associated with potentially harmful behavioral strategies that patients might use to cope with costs, such as delaying or forgoing treatment and skipping medications. Collectively, researchers refer to this impact as financial toxicity.

Medical Xpress·

TheBodyPro | What to know about hepatitis B when switching to tenofovir-sparing antiretroviral regimens - European AIDS Treatment Group

TheBodyPro clinical overviewAs we more frequently prescribe injectables, two-drug therapies, and other novel antiretroviral regimens, a growing proportion of those regimens lack tenofovir. Because tenofovir is used to treat hepatitis B virus (HBV) and is partially protective against new HBV infection, providers need to consider the risk of new or reactivated HBV before switching a patient to a tenofovir-sparing regimen. “I think we are very much in, and entering, an era where increasingly more therapeutic options for antiretroviral therapy and PrEP are going to be without tenofovir,” said H. Nina Kim, M. D., M. Sc., a professor of medicine at University of Washington’s Division of Allergy and Infectious Diseases. Kim co-authored a viewpoint paper this May in Clinical Infectious Diseases highlighting the issue so that clinicians can protect patients against potentially harmful reactivations and new HBV infections. “Many of these reactivations may be subclinical with mild rise in liver enzymes,” Kim said.

European AIDS Treatment Group·